Regenerative SportsCare Institute, New York, NY, USA.
Department of Physiatry, Hospital for Special Surgery, 535 E. 70th Street, New York, NY, 10021, USA.
Int Orthop. 2022 Jun;46(6):1381-1385. doi: 10.1007/s00264-022-05389-y. Epub 2022 Mar 28.
This study aimed to assess clinical outcomes following intradiscal injections of higher-concentration (> 10 ×) platelet-rich plasma (PRP) in patients with chronic lumbar discogenic pain and to compare outcomes with a historical cohort.
This retrospective study included 37 patients who received intradiscal injections of higher-concentration (> 10 ×) PRP and had post-procedure outcomes data (visual numerical scale pain score, Functional Rating Index [FRI], and NASS Patient Satisfaction Index). Outcomes were compared to a historical cohort of 29 patients who received intradiscal injections of < 5X PRP.
Pain and FRI scores significantly improved by 3.4 ± 2.5 and 46.4 ± 27.6, respectively, at 18.3 ± 13.3 months following intradiscal injections of > 10 × PRP (p < 0.001). These improvements were greater than those reported by the historical cohort (1.7 ± 1.6 and 33.7 ± 12.3; p = 0.004 and 0.016, respectively). Additionally, the satisfaction rate was higher in patients receiving > 10 × PRP compared to those receiving < 5 × PRP (81% vs. 55%; p = 0.032).
Findings from this study suggest that clinical outcomes can be optimized by using PRP preparations that contain a higher concentration of platelets. Further research is needed to continue to optimize the composition of PRP used to treat patients with lumbar disc disease.
本研究旨在评估在慢性腰椎间盘源性疼痛患者中进行高浓度(> 10×)富含血小板血浆(PRP)椎间盘内注射的临床结果,并与历史队列进行比较。
本回顾性研究纳入了 37 名接受高浓度(> 10×)PRP 椎间盘内注射且具有术后结局数据(视觉数字评分量表疼痛评分、功能评定指数[FRI]和 NASS 患者满意度指数)的患者。将结果与接受<5X PRP 椎间盘内注射的 29 名历史队列患者进行比较。
在接受> 10×PRP 椎间盘内注射后 18.3±13.3 个月时,疼痛和 FRI 评分分别显著改善了 3.4±2.5 和 46.4±27.6(p<0.001)。这些改善明显大于历史队列的报道(1.7±1.6 和 33.7±12.3;p=0.004 和 0.016,分别)。此外,与接受<5X PRP 治疗的患者相比,接受> 10X PRP 治疗的患者的满意度更高(81% vs. 55%;p=0.032)。
本研究结果表明,通过使用含有更高浓度血小板的 PRP 制剂可以优化临床结果。需要进一步的研究来继续优化用于治疗腰椎间盘疾病患者的 PRP 组成。